7 analysts have shared their evaluations of Albemarle (NYSE:ALB) during the recent three months, expressing a mix of bullish and bearish perspectives.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Analysts have set 12-month price targets for Albemarle, revealing an average target of $116.29, a high estimate of $170.00, and a low estimate of $78.00. Highlighting a 9.35% decrease, the current average has fallen from the previous average price target of $128.29.

Diving into Analyst Ratings: An In-Depth Exploration

The standing of Albemarle among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

For valuable insights into Albemarle's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Albemarle analyst ratings.

Delving into Albemarle's Background

Key Indicators: Albemarle's Financial Health

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Albemarle's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -41.37%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.

Net Margin: Albemarle's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -81.99%, the company may encounter challenges in effective cost control.

Return on Equity (ROE): Albemarle's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -13.07%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Albemarle's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.2%, the company may face hurdles in achieving optimal financial performance.

Debt Management: Albemarle's debt-to-equity ratio is below the industry average. With a ratio of 0.45, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Understanding the Relevance of Analyst Ratings

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.